Virus envelope tissue factor promotes infection in mice. (20th February 2019)

• Record Type: Journal Article
• Authors: Sutherland, Michael R.; Simon, Ayo Y.; Shanina, Iryna; Horwitz, Marc S.; Ruf, Wolfram; Pryzdial, Edward L. G.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 17:Number 3(2019)
• Page Start: 482
• Page End: 491
• Publication Date: 2019-02-20
• Subjects: anticoagulant -- coagulation -- protease‐activated receptor -- tissue factor -- virus infection; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.14389
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials The coagulation initiator, tissue factor (TF), is on the herpes simplex virus 1 (HSV1) surface. HSV1 surface TF was examined in mice as an antiviral target since it enhances infection in vitro . HSV1 surface TF facilitated infection of all organs evaluated and anticoagulants were antiviral. Protease activated receptor 2 inhibited infection in vivo and its pre‐activation was antiviral. Summary: Background: Tissue factor (TF) is the essential cell surface initiator of coagulation, and mediates cell signaling through protease‐activated receptor (PAR) 2. Having a diverse cellular distribution, TF is involved in many biological pathways and pathologies. Our earlier work identified host cell‐derived TF on the envelope covering several viruses, and showed its involvement in enhanced cell infection in vitro . Objective: In the current study, we evaluated the in vivo effects of virus surface TF on infection and on the related modulator of infection PAR2. Methods: With the use of herpes simplex virus type 1 (HSV1) as a model enveloped virus, purified HSV1 was generated with or without envelope TF through propagation in a TF‐inducible cell line. Infection was studied after intravenous inoculation of BALB/c, C57BL/6J or C57BL/6J PAR2 knockout mice with 5 × 10 5 plaque‐forming units of HSV1, mimicking viremia. Three days after inoculation, organs were processed, and virus was quantified with plaque‐forming assays and quantitative real‐time PCR. Results: Infection of brain, lung, heart, spinal cord and liver by HSV1 required viral TF. Demonstrating promise as a therapeutic target, virus‐specific anti‐TF mAbs or small‐molecule inhibitors of coagulation inhibited infection. PAR2 modulates HSV1 in vivo as demonstrated with PAR2 knockout mice and PAR2 agonist peptide. Conclusion: TF is a constituent of many permissive host cell types. Therefore, the results presented here may explain why many viruses are correlated with hemostatic abnormalities, and indicate that TF is a novel pan‐specific envelope antiviral target.